Veracyte Inc (FRA:12V)
€ 30.2 -0.2 (-0.66%) Market Cap: 2.33 Bil Enterprise Value: 2.14 Bil PE Ratio: 0 PB Ratio: 2.28 GF Score: 84/100

Veracyte Inc at UBS Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 07:00PM GMT
Release Date Price: €24
Daniel Gregory Brennan
UBS Investment Bank, Research Division - Senior Equity Research Analyst of Healthcare Life Sciences

Good afternoon. My name is Dan Brennan. I cover diagnostic tools and life science -- excuse me, diagnostics tools and pharma services for UBS.

Pleased to be joined on with me -- with me on this virtual stage with the senior management team from Veracyte, Bonnie Anderson, Chairman and CEO; and Keith Kennedy, CFO and COO.

So this is day 2 of the conference, and hopefully, you've been enjoying it. Feel free, by the way, if you log into the webcast, you can pose questions that I'll see on my end, and I'm happy to try to put those forth when we go through the Q&A.

I think that Bonnie is going to go through a slide presentation that's on the website, but she'll direct any of the audience online to find that. And with that, I'll hand it over to Bonnie and say welcome and thanks for joining.

Bonnie H. Anderson
Veracyte, Inc. - Co-Founder, Chairman & CEO

Thank you, Dan. It's really a pleasure to be here. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot